PTC Therapeutics Inc (NASDAQ: PTCT) stock closed at $31.95 on 3/1/24 after a major increase of 13.3%. Moreover, trading volume in this advance was unusually high at 196% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 22.7% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, PTCT is expected to be a major Value Eraser.
PTC Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment